Ads
related to: regeneron pharmaceuticals- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- About Us
Discover the Unique Approach
That Makes Genmab Different.
- Sign Up
Sign Up for Updates, News
and Much More.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Careers
Search results
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Zacks via Yahoo Finance· 4 days agoPer the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication...
CAC 40 Struggles For Direction As Inflation Accelerates
RTT News· 4 days agoFrench stocks struggled for direction on Friday after data showed consumer prices in the country rose at a faster rate this month due to higher energy prices. Consumer prices rose an average ...
Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 6 days agoWet AMD is a large and lucrative pharmaceuticals market. About two million people in the U.S. have...
Biohaven doses first subject in Phase I/II tumour treatment study
Clinical Trials Arena via Yahoo Finance· 5 days agoThis suggests a possible improvement in the clinical efficacy and safety profile for patients....
Recent Circuit Litigation Continues to Highlight “But-For” Causation Requirement for the Government...
JD Supra· 6 days agoThe spotlight is now on U.S. v. Regeneron Pharmaceuticals, Inc., which is currently being briefed by the government and Regeneron before the United States ...
The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.
Investor's Business Daily· 6 days agoLeerink Partners analyst Joseph Schwartz compared the market potential for Insmed's brensocatib to ...
Should You Invest in the iShares Biotechnology ETF (IBB)?
Zacks· 5 days agoFree Report) , a passively managed exchange traded fund launched on 02/05/2001. While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional ...
Intellia’s CRISPR drug shows promise against hereditary angioedema in early-stage trial - Boston...
The Business Journals· 2 days agoBack in 2021, Intellia made history when it successfully edited DNA inside the human body, working...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 4 days agoIt trails only Amgen, and now leads Regeneron Pharmaceuticals and Gilead Sciences. The company is...
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Zacks· 4 days agoFree Report) and Regeneron (REGN Quick QuoteREGN - Free Report) announced that the FDA extended the review period for a regulatory filing seeking label expansion for their blockbuster drug Dupixent ...